Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
To evaluate safety of ultrahypofractionated proton therapy to the prostate and whole pelvis with HDR brachytherapy boost. The technique will be deemed safe if 10% of patients experience a CTCAE grade 3 or higher genitourinary or gastrointestinal toxicity cumulatively over the first year of treatment.To evaluate for multiple domains of …
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
CompassHER2 RD (A011801) is a randomized trial in patients with residual disease after a predefined course of neoadjuvant HER2-directed treatment.
This is a study for patients who have Acute Myeloid Leukemia who previously had Myelodysplastic Syndrome that were treated with Azacitidine or Decitabine.
The aim of this study is to biobank blood and stool samples of healthy individuals receiving β-hydroxybutyrate (BHB) supplementation. Additionally, this study will determine whether BHB supplementation increases serum BHB levels and leads to changes in T cell phenotype, including composition (i.e. CD4/CD8), and cytokine secretion. BHB supplementation will be …
Please refer to Section 4 of the full protocol (Objectives) Please refer to Section 18.4 of the full protocol (Analysis of Primary Endpoints) Please refer to Section 18.5 of the full protocol (Analysis of Secondary and Exploratory Endpoints)
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
This is a study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
